These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 34706253)
21. Mechanism underlying the development of myeloproliferative neoplasms through mutant calreticulin. Edahiro Y; Araki M; Komatsu N Cancer Sci; 2020 Aug; 111(8):2682-2688. PubMed ID: 32462673 [TBL] [Abstract][Full Text] [Related]
22. Molecular classification of myeloproliferative neoplasms-pros and cons. Qureshi M; Harrison C Curr Hematol Malig Rep; 2013 Dec; 8(4):342-50. PubMed ID: 24091831 [TBL] [Abstract][Full Text] [Related]
30. Validation of a molecular diagnostic assay for CALR exon 9 indels in myeloproliferative neoplasms: identification of coexisting JAK2 and CALR mutations and a novel 9 bp deletion in CALR. Murugesan G; Guenther-Johnson J; Mularo F; Cook JR; Daly TM Int J Lab Hematol; 2016 Jun; 38(3):284-97. PubMed ID: 27018326 [TBL] [Abstract][Full Text] [Related]
31. CALR mutations in myeloproliferative neoplasms: hidden behind the reticulum. Guglielmelli P; Nangalia J; Green AR; Vannucchi AM Am J Hematol; 2014 May; 89(5):453-6. PubMed ID: 24458922 [No Abstract] [Full Text] [Related]
32. The role of LNK/SH2B3 genetic alterations in myeloproliferative neoplasms and other hematological disorders. Maslah N; Cassinat B; Verger E; Kiladjian JJ; Velazquez L Leukemia; 2017 Aug; 31(8):1661-1670. PubMed ID: 28484264 [TBL] [Abstract][Full Text] [Related]
33. JAK2 and Beyond: Mutational Study of JAK2V617 in Myeloproliferative Disorders and Haematological Malignancies in Kashmiri population. Syeed N Asian Pac J Cancer Prev; 2019 Dec; 20(12):3611-3615. PubMed ID: 31870101 [TBL] [Abstract][Full Text] [Related]
34. Progress in elucidation of molecular pathophysiology and its application in therapeutic decision-making for myeloproliferative neoplasms. Takenaka K Int J Hematol; 2020 Feb; 111(2):180-181. PubMed ID: 31907735 [No Abstract] [Full Text] [Related]
35. [Relationship between Calreticulin Gene Mutation and JAK2/MPL Negative Myeloproliferative Neoplasms]. Dong L; Shen XL; Wei W Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Oct; 23(5):1532-4. PubMed ID: 26524072 [TBL] [Abstract][Full Text] [Related]
36. CALR gene mutational profile in myeloproliferative neoplasms with non-mutated JAK2 in Moroccan patients: A case series and germline in-frame deletion. Smaili W; Doubaj Y; Laarabi FZ; Lyahyai J; Kerbout M; Mikdame M; Sefiani A Curr Res Transl Med; 2017; 65(1):15-19. PubMed ID: 28340692 [TBL] [Abstract][Full Text] [Related]
37. Common germline variation at the TERT locus contributes to familial clustering of myeloproliferative neoplasms. Jäger R; Harutyunyan AS; Rumi E; Pietra D; Berg T; Olcaydu D; Houlston RS; Cazzola M; Kralovics R Am J Hematol; 2014 Dec; 89(12):1107-10. PubMed ID: 25196853 [TBL] [Abstract][Full Text] [Related]
38. Genomic heterogeneity in myeloproliferative neoplasms and applications to clinical practice. Lee J; Godfrey AL; Nangalia J Blood Rev; 2020 Jul; 42():100708. PubMed ID: 32571583 [TBL] [Abstract][Full Text] [Related]
39. Functional analysis of atypical mutations in exons 13 and 15 of JAK2 gene in myeloproliferative neoplasms. Luo M; Tian T; Zhang Y; Zhang X; Xie J; Xu J; Ren W; Tian C; Wang J; Tan Y; Wang H; Chen X Int J Lab Hematol; 2021 Jun; 43(3):e110-e113. PubMed ID: 33244866 [No Abstract] [Full Text] [Related]
40. Single-cell methods in myeloproliferative neoplasms: old questions, new technologies. O'Sullivan JM; Mead AJ; Psaila B Blood; 2023 Jan; 141(4):380-390. PubMed ID: 36322938 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]